LEXXW - Lexaria's DehydraTECH(TM) Technology Utilized in Amari's Everyday Calm Named a Top CBD Product Pick by New Hope Network
(TheNewswire)
-
- DehydraTECH TM Powers Amari’s Award-Winning Products
Kelowna, British Columbia – TheNewswire - April 14, 2021 –Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or“Lexaria”), a global innovator in drug delivery platforms,announced that its corporate client Amari Corp.’s “EverydayCalm” CBD product was named a Top CBD ProductPick by New Hope Network , host ofthe industry-leading Natural Products Expo conference events. Hundredsof CBD products competed to be among “New Hope Network editors’Top Picks for 2020”.
Eric Gricus, CEO and Founder of Amari, commented,“ Amari went through an extensive selectionprocess for our CBD technology supplier. Lexaria exceeded ourexpectations for product quality, service and pricing. We arethrilled to have the Lexaria team working with Amari to help usdevelop products our customerslove and to win industryaccolades.”
Lexaria’s DehydraTECH TM technologydelivers CBD more quickly and effectively, as evidenced in repeatedstudies, to enhance consumer satisfaction and strengthen brandloyalty.
“Lexaria is delighted to have been able to work withAmari and their award-winning products,” said Chris Bunka, CEO ofLexaria. “DehydraTECH is gaining more widespread consumer supportand we expect to see products utilizing DehydraTECH technology in moreand more stores across America as the year unfolds.”
Lexaria Bioscience Corp.’s proprietary drug deliverytechnology, DehydraTECH™, improves the way active pharmaceuticalingredients (APIs) enter the bloodstream by promoting healthier oralingestion methods and increasing the effectiveness of fat-solubleactive molecules, thereby lowering overalldosing. The Company’s technology can be applied to many differentingestible product formats, including foods, beverages, oralsuspensions, tablets, and capsules. DehydraTECH has repeatedlydemonstrated since 2016 with cannabinoids and nicotine the ability toincrease bio-absorption by up to 5-10x, reduce time of onset from 1 -2 hours to minutes, and mask unwanted tastes; and is planned to befurther evaluated for orally administered bioactive molecules,including anti-virals, cannabinoids, vitamins, non-steroidalanti-inflammatory drugs (NSAIDs), and nicotine. Lexaria has licensedDehydraTECH to multiple companies including a world-leading tobaccoproducer for the development of smokeless, oral-based nicotineproducts and for use in industries that produce cannabinoid beverages,edibles, and oral products. Lexaria operates a licensed in-houseresearch laboratory and holds a robust intellectual property portfoliowith 18 patents granted and approximately 60 patents pendingworldwide. For more information, please visit www.lexariabioscience.com .
About Amari
Founded in 2019, Amari was launched by outdoor enthusiast, EricGricus, for people like him. People who love to be active, but who mayhave noticed as they get older that the spirit is willing, but thebody often has aches and pains and soreness after a day of hiking,skiing or rafting. To create the product, Eric leveraged his more than10 years’ experience working with early-stage CPG companies andcommercializing research from a university setting. Amari formulasblend science and technology to provide authentic, plant-basedremedies that deliver tangible benefits to support a lifestyle ofwellness and vitality, while being rooted in transparency andextensive quality controls.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press releaseincludes forward-looking statements. Statements as such term isdefined under applicable securities laws. These statements may beidentified by words such as "anticipate," "if,""believe," "plan," "estimate,""expect," "intend," "may,""could," "should," "will," and othersimilar expressions. Such forward-looking statements in this pressrelease include, but are not limited to, statements by the companyrelating the Company’s ability to carry out research initiatives,receive regulatory approvals or grants or experience positive effectsor results from any research or study. Such forward-looking statementsare estimates reflecting the Company's best judgment based uponcurrent information and involve a number of risks and uncertainties,and there can be no assurance that the Company will actually achievethe plans, intentions, or expectations disclosed in theseforward-looking statements. As such, you should not place unduereliance on these forward-looking statements. Factors which could cause actualresults to differ materially from those estimated by the Companyinclude, but are not limited to, government regulation and regulatoryapprovals, managing and maintaining growth, the effect of adversepublicity, litigation, competition, scientific discovery, the patentapplication and approval process, potential adverse effects arisingfrom the testing or use of products utilizing the DehydraTECHtechnology, the Company’s ability to maintain existingcollaborations and realize the benefits thereof, delays orcancellations of planned R&D that could occur related to pandemicsor for other reasons, and other factors which may be identified fromtime to time in the Company's public announcements and periodicfilings with the US Securities and Exchange Commission on EDGAR. Thereis no assurance that any of Lexaria’s postulated uses, benefits, oradvantages for the patented and patent-pending technology will in factbe realized in any manner or in any part. No statement herein has beenevaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat,cure or prevent any disease. Any forward-looking statements containedin this release speak only as of the date hereof, and the Companyexpressly disclaims any obligation to update any forward-lookingstatements contained herein, whether as a result of any newinformation, future events, changed circumstances or otherwise, exceptas otherwise required by law.
TheCSE has not reviewed and does not accept responsibility for theadequacy or accuracy of this release.
INVESTOR CONTACT:
Copyright (c) 2021 TheNewswire - All rights reserved.